SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.53 a share - Earnings Preview
SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on October 29 for the period ending September 30 2024
The Cambridge Massachusetts-based company is expected to report a 297.7% increase in revenue to $10.802 million from $2.72 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
LSEG's mean analyst estimate for SAGE Therapeutics Inc is for a loss of $1.53 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 16 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 0.3% in the last three months.
Wall Street's median 12-month price target for SAGE Therapeutics Inc is $10.00, above its last closing price of $8.01.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -1.70 | -1.66 | -1.70 | Missed | -2.5 |
Mar. 31 0001 | -1.64 | -1.65 | -1.80 | Missed | -9.3 |
Dec. 31 2023 | -1.65 | -1.28 | -1.80 | Missed | -40.9 |
Sep. 30 2023 | -2.76 | -2.73 | -3.37 | Missed | -23.4 |
Jun. 30 2023 | -2.56 | -2.55 | -2.68 | Missed | -4.9 |
Mar. 31 2023 | -2.47 | -2.50 | -2.46 | Beat | 1.4 |
Dec. 31 2022 | -2.41 | -2.39 | -2.47 | Missed | -3.5 |
Sep. 30 2022 | -2.24 | -2.21 | -2.31 | Missed | -4.7 |
This summary was machine generated October 27 at 14:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
